Key result
Atrial fibrillation in patients on hemodialysis has a prevalence of up to 27% and a stroke incidence of approximately 5%, while evidence for oral anticoagulation remains contradictory.
Why the study?
Current evidence for anticoagulation in hemodialysis patients with AF relies on contradictory observational data, and hemodialysis patients were excluded from randomized trials of direct oral anticoagulants.
Does oral anticoagulation improve stroke prevention without excessive hemorrhage risk in patients with end-stage renal disease on hemodialysis with atrial fibrillation?
Design
Narrative review
Authors
Loading...
Contradictory anticoagulation evidence in HD patients with AF warrants clinical caution; leaves open dedicated DOAC trials.
Does oral anticoagulation improve stroke prevention without excessive hemorrhage risk in patients with end-stage renal disease on hemodialysis with atrial fibrillation?
This review highlights the lack of clear evidence for anticoagulation in hemodialysis patients with atrial fibrillation and discusses the potential role of DOACs based on their pharmacokinetic profiles.
Königsbrügge et al. (2019) conducted a review in Atrial fibrillation in end-stage renal disease on hemodialysis. Oral anticoagulation was evaluated. Atrial fibrillation in patients on hemodialysis has a prevalence of up to 27% and a stroke incidence of approximately 5%, while evidence for oral anticoagulation remains contradictory.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: